Search

Subject immunotherapy -- multiple myeloma -- relapsed refractory

1. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. Issue 1 (15th January 2022)

Authors:
Fazio, Francesca; Franceschini, Luca; Tomarchio, Valeria; Rago, Angela; Garzia, Maria Grazia; Cupelli, Luca; Bongarzoni, Velia; Andriani, Alessandro; Gumenyuk, Svitlana; Tafuri, Agostino; Siniscalchi, Agostina; Piciocchi, Alfonso; De Fabritiis, Paolo; De Rosa, Luca; Caravita di Toritto, Tommaso; ...
Journal:
EJHaem
Issue:
Volume 3:Issue 1(2022)
Page Start:
121
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • immunotherapy -- multiple myeloma -- relapsed refractory 1